Lentiviral and AAV-mediated expression of palivizumab offfer protection against Respiratory Syncytial Virus infection

Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model.


Fig: In vitro production of palivizumab from rAAV2/8 and rSIV.F/HN. HEK293T cells were (A) transfected with rAAV and rSIV vector genomes expressing palivizumab or GLux, were (B) transduced with rAAV and rSIV vector particles expressing palivizumab or remained naïve to treatment; 48 h post-transfection/transduction, palivizumab levels in tissue culture supernatant was measured using a Human IgG ELISA. In several cases the errors are obscured by the mean bar, where appropriate, only positive error bars are shown. The dotted line represents the limit of detection (LOD). Differences between treatment and naïve control groups were evaluated using the Kruskal–Wallis test with Dunn’s post hoc multiple comparison test.

Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.

Antepowicz, A., Habib, O., Kirsebom, F. et al. Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection. Sci Rep 11, 15694 (2021). https://doi.org/10.1038/s41598-021-95150-z

Leave a Reply

Your email address will not be published. Required fields are marked *